Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2304]

PC14586: The first orally bioavailable small molecule reactivator of Y220C...

Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )

First-line pembrolizumab plus chemotherapy for patients with advanced squamous...

Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General...

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic

Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

Challenges and solutions in PD-L1 testing in NSCLC

Prof Frédérique Penault-Llorca - Centre Jean Perrin, Clermont-Ferrand, France

Challenges and solutions in PD-L1 testing in NSCLC ( Prof Frédérique Penault-Llorca - Centre Jean Perrin, Clermont-Ferrand, France )

Promise of personalised medicine for patients with prostate cancer

Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt...

Promise of personalised medicine for patients with prostate cancer ( Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt Attard )

Latest developments in the treatment of mRCC

Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald

Latest developments in the treatment of mRCC ( Prof Javier Puente, Prof Jens Bedke, Prof James Larkin and Prof Viktor Grünwald )

Long term response to apalutamide and other updates impacting patients with...

Prof Axel Merseburger and Prof Matthew Smith

Long term response to apalutamide and other updates impacting patients with nmCRPC from ASCO GU 2021 ( Prof Axel Merseburger and Prof Matthew Smith )

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early...

Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt...

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment? ( Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard )

Current treatment standards for primary ovarian cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Current treatment standards for primary ovarian cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Evolving medical treatment in advanced/recurrent endometrial cancer

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Evolving medical treatment in advanced/recurrent endometrial cancer ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

More from ecancer